GenSight Biologics S.A.

SIGHT

FR0013183985

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 10:03:25 2024-04-26 am EDT			5-day change	1st Jan Change
0.4195 ^EUR	+0.36%		+2.32%	-8.80%

Apr. 05	GenSight: financial visibility assured until the end of April	CF
Mar. 25	GenSight: share price falls, limited financial visibility	CF

GenSight Biologics S.A.(ENXTPA:SIGHT) dropped from S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about GenSight Biologics S.A.

GenSight: financial visibility assured until the end of April	Apr. 05	CF
GenSight: share price falls, limited financial visibility	Mar. 25	CF
GenSight Biologics S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ®? Injections Four Years After One-Time Administration	Mar. 20	CI
GenSight Biologics: results on Lumevoq® gene therapy	Mar. 12	CF
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024	Mar. 12	CI
GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024	Mar. 06	CI
GenSight: Goldman Sachs exceeds 5% threshold	Feb. 16	CF
GenSight Biologics Raises EUR5 Million Fresh Capital from New, Existing Investors	Feb. 08	MT
Gensight Biologics S.A. Announces CFO Changes	Jan. 25	CI
GenSight Biologics Announces Board Changes	Jan. 16	CI
GenSight: UK notice keeps hopes alive	Dec. 27	CF
GenSight appoints new CEO	Dec. 22	CF
France's GenSight Biologics Appoints New CEO	Dec. 22	MT
GenSight Biologics S.A. Announces CEO Changes	Dec. 22	CI
GenSight: Sofinnova Partners exceeds 20% stake	Nov. 27	CF
GenSight: CDC falls below 5% stake	Nov. 27	CF
GenSight Biologics Raises EUR4.7 Million via Private Placement, Public Offering	Nov. 21	MT
Gensight Biologics S.A. Confirms Second Successful GMP Batch of Lumevoq	Nov. 15	CI
GenSight: a breath of fresh air with new financing	Nov. 13	CF
GenSight Biologics S.A. Announces Preliminary Assay Indicating Successful Manufacture of Second LUMEVOQ® GMP Batch	Nov. 13	CI
GenSight Biologics S.A. announced that it has received ?4 million in funding from Sofinnova Partners SAS, The Invus Group, LLC, UPMC Enterprises	Nov. 12	CI
European Medicines Regulator OKs Study Protocol for Gensight Biologics' Late-stage Trial of Vision Loss Drug; Stock Surges	23-09-27	MT
GenSight: market hails progress on Lumevoq	23-09-27	CF
GenSight Biologics Provides Update on European Medicines Agency Scientific Advice for LUMEVOQ	23-09-27	CI

GenSight Biologics S.A. specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives. At the end of 2023, the company had a portfolio of 2 products, including 1 in phase III clinical development (Lumevoq for the treatment of Leber's hereditary optic neuropathy) and 1 in phase I/II clinical development (GS030 for the treatment of retinitis pigmentosa).

Sector

Biotechnology & Medical Research

Calendar

2024-05-28 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for GenSight Biologics S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.4195 EUR

Average target price

0.4 EUR

Spread / Average Target

-4.65%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GENSIGHT BIOLOGICS S.A.	-8.80%	34.94M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs